Most interestingly, high PRKD1 expression is a poor prognostic factor in ER+ tamoxifen-treated breast tumors, suggesting that PKD1 participates to endocrine therapy resistance in the clinics [6]. This evidence concerns the gene PRKD1 and breast neoplasm.